Alluvi, previously BI 4744, represents a promising advance in obesity treatment. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling efficacy in https://alluviretatrutide236902.bloggerchest.com/profile